Edelweiss has come out with its first quarter (April-June) earnings estimates for the pharmaceuticals sector. The brokerage house expects Natco Pharma to report a 34.1 percent degrowth quarter-on-quarter (growth of 47.8 percent year-on-year) in net profit at Rs 39.7 crore.
Net Sales are expected to decrease by 29 percent Q-o-Q (up 29.1 percent Y-o-Y) to Rs 288.8 crore, according to Edelweiss.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 30.3 percent Q-o-Q (up 12.2 percent Y-o-Y) to Rs 64.5 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
